Detalhe da pesquisa
1.
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
J Neurooncol
; 144(2): 303-311, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392595
2.
Managing painful procedures in children with cancer.
J Pediatr Hematol Oncol
; 33(2): 119-27, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21285907